Status and phase
Conditions
Treatments
About
This study will evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab (PDS) in Participants with Diabetic Macular Edema (DME) when treated every 24 weeks (Q24W) compared with intravitreal ranibizumab 0.5 mg every 4 weeks (Q4W).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Study eye
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
634 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal